Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 2/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | S100A4 | P26447 | 1/20 | 0.42 |
| ▸ | PRNP | P04156 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30421706 | 1.00 | CYP1A2 (0.61) | CYP1A2FFAR1KDM4EALDH1A1HPGD | |
| SCHEMBL14273063 | 0.85 | CYP1A2 (0.73) | CYP1A2FFAR1KDM4EALDH1A1HPGD | |
| SCHEMBL8705447 | 0.82 | HTR7 (0.49) | CYP1A2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30421739 | 0.82 | HTR7 (0.44) | CYP1A2FFAR1KDM4EALDH1A1HPGD | |
| SCHEMBL15916105 | 0.82 | SMN1; SMN2 (0.52) | CYP1A2ALDH1A1HSD17B10MCL1HTR7 | |
| SCHEMBL30422241 | 0.81 | HTR7 (0.51) | ALDH1A1HPGDHSD17B10CDC25BHTR7 | |
| SCHEMBL11603953 | 0.81 | HTR7 (0.51) | ALDH1A1HPGDHSD17B10CDC25BHTR7 | |
| SCHEMBL6299141 | 0.79 | HTR7 (0.46) | CYP1A2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30184557 | 0.79 | HTR7 (0.46) | CYP1A2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL11871456 | 0.78 | MAPT (0.52) | CYP1A2KDM4EALDH1A1HPGDHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024074611-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2024-04-11 | — | — | WO | disclosed |
| WO-2021074898-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2021-04-22 | — | — | WO | disclosed |
| EP-1569919-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-04-18 | — | — | EP | disclosed |
| EP-1569919-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-04-18 | — | — | EP | disclosed |
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-7642277-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-05 | — | — | US | disclosed |
| US-7642277-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-05 | — | — | US | disclosed |
| US-7642277-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-05 | — | — | US | disclosed |
| US-7317125-B2 | Diacylglycerol acyltransferase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7317125-B2 | Diacylglycerol acyltransferase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-7317125-B2 | Diacylglycerol acyltransferase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-01-08 | — | — | US | disclosed |
| EP-1848687-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | F. Hoffmann-Roche AG (CH) | 2007-10-31 | — | — | EP | disclosed |
| US-20060178532-A1 | Diacylglycerol acyltransferase inhibitors | VIA PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006082010-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-10 | — | — | WO | disclosed |
| EP-1569919-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
| US-20050054639-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
| WO-2004050643-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | CYP1A2 585/4885FFAR1 74/4885KDM4E 3467/4885 |
| US-20050054639-A1 | Non-nucleoside reverse transcriptase inhibitors | NAT1, SUB1, RTF2 | CYP1A2 289/4885FFAR1 2943/4885KDM4E 2654/4885 |
| US-20060178532-A1 | Diacylglycerol acyltransferase inhibitors | DGAT2, DGAT1, LCAT | CYP1A2 753/4885FFAR1 245/4885KDM4E 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.